RRML - Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2020): 1.027

Rejection rate (2020): 75%

Română English


Clarivate analytics (ISI) Impact factor


Advanced search


Top 10 downloaded articles
- May 2022 -
 
Approaching Risk Management in... 16
Screening of a novel BRCA2 mut... 14
Romanian Review of Laboratory ... 9
Matrix-assisted Laser Desorpti... 9
Proposal of a prediction model... 9
The evaluation of a diagnostic... 8
The evaluation of the preanaly... 7
Associations of serum expressi... 7
Downregulation of hsa-miR-4328... 7
Clinical significance of serum... 6

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 28(2)/2020 DOI:10.2478/rrlm-2020-0007
XML
TXT

Review

Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia

Letitia Elena Radu, Roxana Corina Sfetea, Constantin Virgiliu Arion, Anca Colita

Correspondence should be addressed to: Letitia Elena Radu

Abstract:

cardiac impairment during the treatment of pediatric patients is extremely important, both for modulating future chemotherapy and for administering cardioprotective agents. Long term monitoring after chemotherapy helps to identify the risk of late cardiotoxicity among cancer survivors. There are several biomarkers, already in use or still under study, which may represent an operator-independent alternative for echocardiography in the diagnosis of cardiotoxicity. In case of cardiac damage, the clinician has options for treating or limiting the progression, either with the use of already approved agents, such as Dexrazoxane, or by administrating other cardioprotective drugs. International experts are still attempting to establish the best algorithm for early detection of cardiotoxicity, as well as the most efficient treatment plan in case of already existing myocardial damage in these patients. We present a review on treatment-related cardiotoxicity, including mechanisms of development, useful biomarkers and treatment options, after carefully analyzing specialty literature.

Keywords: acute lymphoblastic leukemia, cardiotoxicity, biomarkers, cardioprotective agents

Received: 11.10.2019
Accepted: 31.12.2019
Published: 5.2.2020

 
  PDF Download full text PDF
(438 KB)
     
 
How to cite
Radu LE, Sfetea RC, Arion CV, Colita A. Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia. Rev Romana Med Lab. 2020;28(2):133-44. DOI:10.2478/rrlm-2020-0007